SEARCH RESULTS FOR:
Louise Pearce
GLOBAL MINING DIRECTOR, ERM
ERM works with clients all over the world, helping them to progress their ESG priorities and create innovative solutions to sustainability challenges.
Olivier Schorochoff & Weid Vereycken
MANAGING DIRECTOR & REGIONAL MANAGER HAUT-KATANGA AND LUALABA, GARDAWORLD
MACIG 2022
GardaWorld is the largest privately-owned security services company in the world, with an annual turnover of around US$4 billion, a total of 120,000 employees.
William Tan
GENERAL MANAGER, EMERSON AUTOMATION SOLUTIONS
Emerson explains its role in the digital transformation of the process industries in Singapore.
Kenneth Lim
ASSISTANT CHIEF EXECUTIVE (INDUSTRY), MARITIME AND PORT AUTHORITY OF SINGAPORE
The Maritime and Port Authority in Singapore explains its initiatives to retain its global leadership.
Andrew Grove
MANAGING DIRECTOR, CHESSER RESOURCES
MACIG 2022
Chesser Resources explains progress at its Diamba Sud project in Senegal.
Mouhammed Kebe
PARTNER, GENI AND KEBE
MACIG 2022
Gene and Kebe comment on how West Africa is evolving to better welcome investments.
Wayne Yap
EXECUTIVE DIRECTOR, ASPRI (ASSOCIATION OF PROCESS INDUSTRY)
ASPRI is a Singapore trade association that represents the interests of more than 550 corporate members in the Process Industry.
Caigen Wang
FOUNDER AND CEO, TIETTO MINERALS
"We are absolutely thrilled to have successfully completed an A$130 million two-tranche placement with no debt. Abujar is now fully funded to commence production in late CY2022."
Joshua Olmsted
PRESIDENT AND COO – AMERICAS, FREEPORT-MCMORAN
Freeport-McMoral updates GBR on its strategy for Chile.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
